Threshold Pharmaceuticals (acquired by Molecular Templates) is Pharmaceuticals in United States that focus on Molecular Templates Inc business. Founded in 2001. They cover business area such as Molecular Templates Inc, therapeutic agent, tumor cell, individual, cancer.
2001
( 23 years old in 2024 )
Molecular Templates Inc
-
170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
Private
Molecular Templates Inctherapeutic agenttumor cellindividualcancer
* We use standard office opening hours in near Threshold Pharmaceuticals (acquired by Molecular Templates)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Threshold Pharmaceuticals (acquired By Molecular Templates) is Pharmaceuticals business from United States that founded in 2001 (23 years old in 2024), Threshold Pharmaceuticals (acquired by Molecular Templates) business is focusing on Molecular Templates Inc.
Threshold Pharmaceuticals (acquired by Molecular Templates) headquarter office and corporate office address is located in 170 Harbor Way Suite 300 South San Francisco, CA 94080 United States.
Threshold Pharmaceuticals (acquired by Molecular Templates) was founded in United States.
In 2024, Threshold Pharmaceuticals (acquired by Molecular Templates) is currently focus on Molecular Templates Inc sector.
Above is snippet of Google Trends for "Molecular Templates Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Threshold Pharmaceuticals (acquired by Molecular Templates), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
